PROPOXYPHENE suppliers

Properties

Melting point:：

75-76°

alpha ：

D25 +67.3° (c = 0.6 in chloroform)

Boiling point:：

475.43°C (rough estimate)

Density ：

1.0751 (rough estimate)

refractive index ：

1.5614 (estimate)

Flash point:：

2℃

storage temp. ：

2-8°C

pka：

pKa 6.3(50% aq EtOH) (Uncertain)

SecurityInformation

Symbol(GHS) ：

GHS02,GHS07

Signal word ：

Danger

Hazard statements ：

H225-H302+H312+H332-H319

Precautionary statements ：

P210-P261-P302+P352+P312-P304+P340+P312-P337+P313-P403+P235

Hazard Codes ：

F,Xn,T

Risk Statements ：

11-20/21/22-36-52/53-25

Safety Statements ：

16-26-36/37-61-45-36/37/39

RIDADR ：

3249

WGK Germany ：

2

HazardClass ：

6.1(b)

PackingGroup ：

III

Toxicity：

An opioid analgesic similar in structure to methadone. It is a much less potent analgesic than morphine and is devoid of antipyretic or anti-inflammatory effects. Its side effects are qualitatively similar to codeine. The clinical indications for propoxyphene are much the same as for aspirin. It is used when the degree of analgesia required is less than that produced by morphine. Recent clinical trials suggest that propoxyphene is no more effective in controlling mild pain than is aspirin. Because they act by different mechanisms, aspirin and propoxyphene have often been given in combination. Recently, there has been a trend away from use of propoxyphene because its weak analgesic properties do not compensate for other problems with its use. Interestingly, the analgesic activity of propoxyphene resides largely in the dextrorotatory isomer, whereas the antitussive effect is produced primarily by the levorotatory isomer. The use of propoxyphene was banned in the United States in November 2010. The oral LD50 in rats is 84 mg/kg.